AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT
KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.
Therapy Area
Bavarian Nordic secures four-year UK vaccine supply deal
Pelthos and Castle Creek plan merger to target skin diseases
Podcast: ESMO26: Major readouts from the 2026 congress
ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial
ESMO26: KEYNOTE-C93 backs chemo-free Keytruda in dMMR endometrial cancer
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
ESMO26: Bayer’s Phase III Nubeqa win leaves survival and abiraterone questions open
